| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6758214 | VERO BIOTECH | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
Feb, 2022
(1 year, 7 months ago) | |
| US11291793 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US8821801 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US8226916 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US8609028 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US9956373 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US11383059 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US10124142 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US9522249 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US10814092 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2025
(2 years from now) | |
| US8057742 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2026
(2 years from now) | |
| US7947227 | VERO BIOTECH | Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(3 years from now) | |
| US7618594 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(3 years from now) | |
| US7560076 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Apr, 2027
(3 years from now) | |
| US9701538 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2029
(5 years from now) | |
| US9604028 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Aug, 2029
(5 years from now) | |
| US10926054 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Aug, 2029
(5 years from now) | |
| US8944049 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Aug, 2029
(5 years from now) | |
| US11103669 | VERO BIOTECH | Nitric oxide therapies |
Jun, 2030
(6 years from now) | |
| US8607785 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Jul, 2030
(6 years from now) | |
| US10737051 | VERO BIOTECH | Nitrogen dioxide storage device |
Oct, 2035
(12 years from now) | |
| US10213572 | VERO BIOTECH | Nitrogen dioxide storage cassette |
Feb, 2036
(12 years from now) | |
Genosyl is owned by Vero Biotech.
Genosyl contains Nitric Oxide.
Genosyl has a total of 22 drug patents out of which 1 drug patent has expired.
Expired drug patents of Genosyl are:
- US6758214
Genosyl was authorised for market use on 20 December, 2019.
Genosyl is available in gas;inhalation dosage forms.
Genosyl can be used as a method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia, a method of delivering nitric oxide to a patient.
The generics of Genosyl are possible to be released after 12 February, 2036.
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: A method of delivering nitric oxide to a patient; A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia
Dosage: GAS;INHALATION
GENOSYL family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11554241 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(1 year, 10 months from now) | |
| US11511252 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Sep, 2029
(5 years from now) | |
| US11672938 | VERO BIOTECH INC | Start-up protocols for nitric oxide delivery device |
Jul, 2040
(16 years from now) | |
Genosyl is owned by Vero Biotech Inc.
Genosyl contains Nitric Oxide.
Genosyl has a total of 3 drug patents out of which 0 drug patents have expired.
Genosyl was authorised for market use on 20 December, 2019.
Genosyl is available in gas;inhalation dosage forms.
Genosyl can be used as a method of delivering nitric oxide to a patient.
The generics of Genosyl are possible to be released after 22 July, 2040.
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: A method of delivering nitric oxide to a patient
Dosage: GAS;INHALATION
GENOSYL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic